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abstract
Accurately measuring the brain concentration of a neurotherapeutic is critical in determining its pharmacokinetic
proﬁle in vivo. Biologics are potential therapeutics for neurologic diseases and biologics fused to an antibody
targeting a transcytosis receptor at the Blood-Brain Barrier, designated as antibody-biologic fusion proteins,
are Blood-Brain Barrier penetrating neurotherapeutics. The use of sandwich immunosorbent assays to measure
concentrations of antibody-biologic fusion proteins in brain homogenates has become increasingly popular.
The raw brain homogenate contains many proteins and other macromolecules that can cause a matrix effect,
potentially interfering with the limit of detection of such assays and reduce the overall sample signal. Further,
the low sample loading volumes while running these assays can reduce the sample signal. Our aim was therefore
to optimize the existing tissue sample preparation and processing to concentrate the sample to elevate the signal
of the analyte. Here, we present a protocol for concentrating and increasing the signal of transferrin receptor
antibody-biologic fusion proteins in mouse brain homogenates using the Amicon Ultra Centrifugal ﬁlters.
• The presented method uses the Amicon Ultra Centrifugal ﬁlters to concentrate mouse brain tissue
homogenates.
• The concentrated brain tissue homogenates are then assayed using standard sandwich enzyme-linked
immunosorbent assay (ELISA) protocols.
• This method improves upon the traditional brain homogenization procedure and ELISA measurements for
antibody-biologic fusion proteins by effectively concentrating brain tissue homogenates.
© 2021 The Author(s). Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Introduction
The Blood-Brain Barrier (BBB), formed by the brain microvascular endothelial cells that are
sealed together by tight junctions, is a highly selective semipermeable membrane that regulates the
movement of ions, molecules, and nutrients into the brain, maintaining homeostasis and protects
the brain from toxins and pathogens [1]. The BBB also restricts the entry of drugs into the central
nervous system (CNS) and acts as a major obstacle to brain drug delivery [2]. In vivo techniques
provide the highest sensitivity and more reliable reference information for testing and validating other
BBB permeability models [3]. Determining the brain pharmacokinetic proﬁle of a CNS permeant drug
is dependent on accurately measuring the drug concentration in the brain. Over the last decade,
there has been an increase in the number of studies using sandwich immunoassays to measure
brain concentrations of BBB-penetrating antibody (IgG)-biologic fusion proteins [4–6]. These studies
utilize sandwich immunoassays to measure transferrin receptor antibody-biologic fusion protein
concentrations in brain homogenate-derived supernatants. However, homogenization of the brain
tissue in the homogenization buffer dilutes the detection signal. Furthermore, the brain contains many
proteins and other macromolecules that, if excluded before retrieving the supernatant containing the
CNS therapeutic of interest, may increase the assay signal. These proteins and macromolecules can
cause the matrix effect, adversely impacting the limit of the detection of the assay [7]. To increase
the signal-to-noise ratio of the sandwich ELISA to measure BBB-penetrating transferrin receptor IgGbiologic fusion proteins, we developed a method to concentrate the brain homogenate supernatants
using the Amicon Ultra Centrifugal ﬁlters. This method concentrates the sample volume and improves
the overall signal in the ELISA. This entire process is shown in Fig. 1.
This protocol was tested with the fusion protein of a chimeric transferrin receptor monoclonal
antibody and erythropoietin (cTfRMAb-EPO) and a mutant form of the fusion protein (cTfRMAbN292G-EPO). The cTfRMAb-N292G-EPO fusion protein was engineered by removing the Fc N-linked
glycosylation site at position 292 in the heavy chain of the TfRMAb with substitution of the amino
acid asparagine (Asn) with glycine (Gly) [8].
Materials
1. 4mL glass scintillation
Pennsylvania, USA).

vials

(#03-339-23B

or

#03-339-25B;

Fisherbrand,

Pittsburgh,
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Fig. 1. Brain homogenization and Amicon concentration. The perfused mouse brain is homogenized and processed. The
homogenized supernatant is separated from the brain pellet via centrifugation and either directly run on an enzyme-linked
immunosorbent assay (ELISA) (represented by the pink dotted arrow) or put through the Amicon centrifugation. The Amicon
retentate concentrate is further run on an ELISA. The ﬁgure was created using BioRender.com.

2. 2 mL Eppendorf® Safe-Lock microcentrifuge tubes (#EP022363344; Millipore Sigma, Burlington,
Massachusetts, USA).
3. Pulverizer.
4. Handheld tissue homogenizer (#H100197; Waverly Scientiﬁc, Waverly, Iowa, USA).
5. T-PERTM Tissue Protein Extraction Reagent (#78510; Thermo Fisher Scientiﬁc, Waltham,
Massachusetts, USA).
6. cOmpleteTM Mini-EDTA-free protease inhibitor cocktail tablets (#4693159001; Sigma, St. Louis,
Missouri, USA).
7. Shaker.
8. Dry Ice.
9. Ice.
10. Eppendorf® Centrifuge 5417R (Z366021; Sigma Aldrich, St. Louis, Missouri, USA).
11. Weighing scale for brain hemispheres.
12. Euthasol (stock concentration: 390 mg/mL. Each mL contains 390 mg pentobarbital sodium and
50 mg phenytoin sodium). Euthasol was diluted to 1:10 with sterile saline.
13. Perfused mice brain hemispheres.
14. Amicon Ultra 2 mL 50 kDa Protein Puriﬁcation and Concentration Filters (#UFC205024;
Millipore Sigma, Burlington, Massachusetts, USA).
15. Eppendorf® Centrifuge 5810R with the swinging bucket rotor A-4-62 (#EP022628168; Sigma
Aldrich, St. Louis, Missouri, USA).
16. Tris Buffer Saline (TBS): 0.05 M Tris/0.15 M NaCl/pH 7.4.
17. TBST: TBS + 0.05% Tween-20.
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18. Chimeric transferrin receptor antibody-biologic fusion protein therapeutic: cTfRMAb-EPO (0.7
mg/mL; Genscript, Piscataway, New Jersey, USA).
19. Chimeric transferrin receptor antibody-biologic fusion protein therapeutic: cTfRMAb-N292GEPO (0.78 mg/mL; Genscript, Piscataway, New Jersey, USA).
20. Transferrin receptor antibody-biologic fusion protein therapeutic vehicle: 96 mM glycine, 28
mM Tris, 148mM NaCl, 0.01% Polysorbate 80, pH=5.5.
21. Recombinant human EPO receptor (EPOR)/Fc fusion protein (R&D System #963-ER-050).
22. 0.1M NaHCO3 /pH 8.5.
23. TBSB: 0.01M Tris/0.15M NaCl/pH 7.4/1% bovine serum albumin (BSA).
24. Goat anti-mouse light chain (kappa) antibody conjugated to alkaline phosphatase (GAM-AP) (#
A90-119AP; Bethyl, Montgomery, Texas, USA).
25. P-nitrophenyl phosphate (PNPP) (#P5994; Sigma Aldrich, St. Louis, Missouri, USA).
26. Glycine Buffer/pH 10.4.
27. 1.2M NaOH.
28. 96 well NUNC Maxisorp ﬂatbottom 96 TS (#501123685; Fisher Scientiﬁc, Waltham,
Massachusetts, USA).
29. SpectraMax Plus 384 Microplate Reader (Molecular Devices; San Jose, California, USA).
30. SoftMax Pro Software (Molecular Devices; San Jose, California, USA).
31. GraphPad Prism 8 Software (GraphPad Software Inc.; San Diego, California, USA).
Methods
Mouse animal study
All animal procedures were approved by the University of La Verne Institutional Animal Care and
Use Committee (Protocol No. LV0012d). Eight-week-old male C57BL/6J mice were obtained from the
Jackson Laboratory (Bar Harbor, ME). The mice were provided constant access to food and water and
were maintained on a 12 h light/12 h dark cycle.
The mice were injected intravenously with 0.3 mg/kg (n=3) or 3 mg/kg (n=4), or intraperitoneally
with 3 mg/kg (n=6) of cTfRMAb-EPO. A separate group of age-matched mice were injected
intravenously with 0.3 mg/kg (n=3) or 3 mg/kg (n=6), or intraperitoneally with 3 mg/kg (n=3) of the
mutant cTfRMAb-N292G-EPO fusion protein. Control mice were dosed intraperitoneally with saline
(n=4). Twenty-four-hours after the initial injection, the mice were anesthetized with a lethal dose
of Euthasol (150 mg/kg, intraperitoneally) and transcardially perfused with ice-cold phosphate buffer
saline (PBS). The brain hemispheres were harvested and stored at -80˚C until use.
Brain pulverization protocol
1. Prepare the 4 mL glass scintillation vials to store each individual pulverized brain hemisphere.
Pre-weigh and label the scintillation vials clearly.
2. Place the handheld pulverizer in powdered dry ice for 3 min. This process ensures that the
equipment is cold and prevents the frozen brain hemispheres from warming up and sticking to
the pulverizer.
3. Place frozen brain hemisphere in the chilled pulverizer and pulverize into a ﬁne powder with a
hammer. This process is done over dry ice to maintain the cold temperature.
4. Separate the powdered brain hemisphere into two groups: the brain homogenate group and the
Amicon Ultra Centrifugal Filter separated group.
NOTE: The brain homogenate group consists of the raw brain homogenate samples that have
not been processed using the Amicon Ultra Centrifugal Filter but for which the brain homogenate
supernatants are directly run on the ELISA (Fig. 1). The brain homogenate group was compared to the
Amicon retentate concentrate sample to compare the relative signal between the two samples.
The Amicon Ultra Centrifugal Filter separated group consists of the raw brain homogenate
supernatant samples that run through the Amicon Ultra 2 mL 50 kDa Protein Puriﬁcation and
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Concentration Filter Tubes (Fig. 1). This sample group is further separated between the relevant
Amicon retentate concentrate samples and the extraneous Amicon ﬁltrate samples. The retentate
concentrate sample is the sample that is retained by the Amicon centrifugation process, while the
ﬁltrate sample is the sample that is ﬁltered through and typically discarded.
1. Collect the powdered brain using a pre-chilled metal spatula and place it in pre-chilled scintillation
vials.
2. Quickly weigh the scintillation vials again and note the weight. The weight difference in the preweighed vials and the vials containing the powdered brain is the total brain weight, which is
important for the brain homogenization calculations below.
3. Place the 4 mL scintillation vials with the pulverized brains at -80°C until brain homogenization.
Brain homogenization protocol
1. Make the homogenization buffer by mixing 10 mL of T-PERTM Tissue Protein Extraction Reagent
with 1 tablet of cOmpleteTM Mini-EDTA-free protease inhibitor cocktail tablet.
2. Take out the scintillation vials with the pulverized brains from -80°C and place them on ice.
3. Homogenize the pulverized brain in the homogenization buffer with the handheld tissue
homogenizer for 30 sec. Wash the homogenizer with chilled ice-cold homogenization buffer
between samples.
a For homogenizing the brain homogenate group, put 4 brain volumes (4 μL/mg of the brain)
of ice-cold homogenization buffer (T-PER) into the chilled scintillation vial with the pulverized
brain. Over-dilution of the samples will lead to a lower signal.
b For homogenizing the Amicon Ultra Centrifugal Filter separated group, put 7 brain volumes (7
μL/mg of the brain) of ice-cold homogenization buffer (T-PER) into the chilled scintillation vial
with the pulverized brain. Dilution of the samples is not an issue because the sample will be
concentrated with the Amicon Ultra 2 mL 50 kDa Protein Puriﬁcation and Concentration Filters.
NOTE: the Amicon Ultra 2 mL 50 kDa Protein Puriﬁcation and Concentration Filters can hold a
maximum volume of 2 mL. NOTE: the average weight of the pulverized hemisphere was about
200-220 mg and the average brain homogenate volume based on 7 μL/mg was 1400-1540 μL.
4. Mix the chilled scintillation vials on a shaker at 4°C for 1 h.
5. Pipette out all the brain homogenate into a chilled centrifuge tube. Collect everything to avoid
protein loss and inaccuracies in the calculation.
6. Weigh the centrifuge tubes. Arrange and counterbalance the centrifuge tubes into weight-matched
pairs in the rotor of the Eppendorf centrifuge 5417R. Centrifuge the brain samples at 14,0 0 0xg for
20 min at 4°C.
7. Collect and aliquot (to prevent repeated freeze-thaw cycles) all the supernatant in labeled 2 mL
Eppendorf tubes and freeze all aliquots in the -80°C freezer for long-term storage. If the brain
ELISA is run the following day, keep all tubes in the 4°C refrigerator to avoid freeze-thaw.
Amicon concentration & puriﬁcation protocol
1. Pipette the Amicon Ultra Centrifugal Filter separated group samples into the Amicon Ultra 2 mL 50
kDa Protein Puriﬁcation and Concentration Filters and assemble the Amicon Centrifugation Tubes,
as described by the vendor.
2. Place and balance Amicon Centrifugation Tubes into the A-4-62 swinging bucket rotor of the
Eppendorf® Centrifuge 5810R and centrifuge at 30 0 0xg for 20 min at 4°C.
3. Take each individual Amicon Centrifugation Tube out and pipette up & down vigorously along
the membranes of the Amicon Filter to detach any macromolecules sticking and blocking the
membrane. NOTE: do this step carefully so as not to damage the membrane.
4. Place the Amicon Centrifugation Tubes back into the swinging bucket rotor and centrifuge at
30 0 0xg for 7 min at 4°C.
5. Take each individual Amicon Centrifugation Tube out and pipette up & down vigorously again
along the membranes of the Amicon Filter to detach any macromolecules sticking and blocking
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the membrane. Place the Amicon Centrifugation Tubes back into the A-4-62 swinging bucket rotor
and centrifuge at 30 0 0xg for 5 min at 4°C. This step is repeated until the volume of the Amicon
Centrifugation retentate is below 300 μL.
6. Once the volume of the collected Amicon retentate concentrate sample is below 300 μL, remove
the assembled device from the centrifuge and separate the Amicon Ultra Filter from the ﬁltrate
collection tube.
7. To recover the Amicon retentate concentrate samples, invert the Amicon Ultra Filter device and
concentrate collection tube. Place the inverted Amicon Ultra Filter device back in the Eppendorf®
Centrifuge 5810R with rotor A-4-62 and counterbalance each sample. Spin for 2 min at 10 0 0xg
to transfer the Amicon retentate concentrate samples from the ﬁlter device to the concentrate
collection tube.
8. Aliquot and freeze the ﬁnal samples in the -80°C freezer to prevent repeated freeze-thaw cycles,
unless you are running the brain ELISA the following day. If running the ELISA the next day,
place the Amicon Ultra Centrifugal Filter separated samples in the 4°C refrigerator with the brain
homogenate samples.
Brain ELISA protocol
1. Dilute the recombinant human EPOR/Fc fusion protein with 0.01M of PBS (pH 7.4) so that the
stock is 100 μg/mL. For this, add 500 μL of PBS for the 50 μg of the lyophilized powder of the
recombinant human EPOR/Fc fusion protein. Split this stock solution into 3 aliquots of 167 μL and
freeze it in the -80°C freezer until use.
2. To make the working solution, remove and thaw one aliquot (16.7 μg) and dilute it with 8.35 mL
of 0.1M NaHCO3 (pH 8.5). The concentration is 2 μg/mL and will be enough for 85 wells with each
well containing 0.2 μg of the EPOR/Fc fusion protein. Plate 100 μL per well in the 96 well Nunc
maxisorp ELISA plate and incubate overnight at 4°C.
3. Aspirate off the EPOR/Fc solution from the ELISA plate after overnight incubation. Then wash each
well 3 times with 150 μL of TBST per well.
4. Block each well with 150 μL of TBSB for at least 30 min at room temperature (RT). Prepare the
standards during this blocking step. Both transferrin receptor antibody-EPO fusion proteins are
diluted to 90,0 0 0 ng/mL, 30,0 0 0 ng/mL, 3,0 0 0 ng/mL, 30 0 ng/mL, 30 ng/mL, and 3 ng/mL for the
standards.
5. Aspirate the TBSB and add 100 μL of cTfRMAb-EPO and cTfRMAb-N292G-EPO standards, 200 μL
of the brain homogenate samples including the T-PER brain homogenate blank, and all the Amicon
retentate concentrate sample volume per well and incubate for 2 h at RT.
6. Aspirate the samples from the ELISA plate and wash each well 3 times with 150 μL of TBST.
7. Dilute 17 μL (8.5 μg) of GAM-AP with 8,483 μL of TBST and add 100 μL of the diluted GAM-AP
working solution per well (100 ng/well). This volume is enough for 85 wells. Incubate the ELISA
plate for 45 min at RT.
8. Aspirate off the GAM-AP working solution from the ELISA plate and wash 3 times with 150 μL of
TBST per well.
9. Dilute a 40 mg PNPP tablet in 40 mL of glycine buffer (pH 10.4). Add 100 μL of the PNPP working
solution in each well and incubate for 20 min at RT in the dark. The color of the solution typically
changes immediately, and saturation of the reaction may be reached before 20 min.
10. Add 100 μL of 1.2M NaOH to each well to stop the color reaction. Monitor the color of the solution
in each well carefully. The reaction needs to be stopped before 20 min if the color changes rapidly.
11. Place the plate on a plate reader and read the absorbance at 405 nm. Compute the mean blank
with the blank T-PER brain homogenate samples. Subtract the blank from each individual test
sample and standard, and compute the mean of the blank-corrected test samples and standard
for each group.
Brain concentration calculation
1. The blank-corrected standard curves (appropriate for the speciﬁc cTfRMAb-based fusion protein)
were ﬁt to the one site-speciﬁc binding nonlinear regression curve to determine the total density
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of binding receptor (BM ax ) and the equilibrium dissociation constant (KD ) values using GraphPad
Prism 8.
2. The brain concentrations (ng/mL brain homogenate supernatant) of both TfRMAb antibody-based
fusion proteins are calculated from the formula:
Concentration = (OD × KD )/ (BMax – OD)
The OD is the optical density measured from the plate reader at 405 nm that has been blankcorrected from the T-PER brain homogenate samples.
1 The amount (ng) of cTfRMAb-based fusion proteins (cTfRMAb-N292G-EPO and cTfRMAb-EPO) in the
brain was calculated by multiplying the back-calculated concentration by the volume of the brain
homogenate.
2 The amount of cTfRMAb-N292G-EPO and cTfRMAb-EPO per gram brain (ng/g brain) was calculated
by dividing the amount (ng) of cTfRMAb-based fusion proteins in the brain by the weight of the
brain (g).
Statistical analysis
All data are represented as mean ± standard error of the mean (SEM), and all statistical analyses
were performed using GraphPad Prism 8 (GraphPad Software Inc., La Jolla, CA). To test the effect
of two factors, two-way ANOVA with Holm-Sidak post-test was used. A two-tailed p<0.05 was
considered statistically signiﬁcant.
Methods validation
In our experiment, we used two bivalent, BBB-penetrating cTfRMAb-based fusion proteins
as model BBB-penetrating IgG-biologic fusion proteins and evaluated their brain concentrations
after intravenous and intraperitoneal routes of administration. The reason for selecting these two
TfRMAb-based fusion proteins for method validation was the profound difference in their plasma
concentrations and expected brain concentrations [8]. Saline-treated mice were used to determine the
background signal in the brain homogenates (background of the assay) and limit of detection (LOD)
of the assay as described previously [9].
Each set of Amicon Ultra Centrifugal Filter separated brain homogenates was paired with its brain
homogenate group counterpart (Fig. 2). As expected, the background concentrations (ng/mL of brain
homogenate supernatant) obtained from saline-treated mice for both the Amicon Ultra Centrifugal
Filter separated group (n=4) and the brain homogenate group (n=4) were comparable and ranged
between 0-0.6 ng/mL and 0-0.4 ng/mL (designated as saline concentration threshold), respectively,
and LOD of the assay was 0.8 ng/mL.
For mice treated with the cTfRMAb-EPO (n=13), the concentrations (ng/mL of brain homogenate
supernatant) resulting from the Amicon Ultra Centrifugal Filter separation ranged between 1-54
ng/mL, and those obtained using the regular brain homogenization method ranged between 0.1-4
ng/mL (Fig. 2). All the brain concentrations of mice treated with the cTfRMAb-EPO and separated using
the Amicon Ultra Centrifugal Filters were above the saline concentration threshold. While using the
regular brain homogenate method, eight of the cTfRMAb-EPO-treated mice had brain concentrations
above and ﬁve had brain concentrations below the saline concentration threshold (Fig. 2). Amicon
Ultra Centrifugal Filter separation elevated the brain homogenate concentration of the cTfRMAb-EPO
in all thirteen brain samples tested.
For mice treated with the mutant cTfRMAb-N292G-EPO (n=12), the concentrations (ng/mL of
brain homogenate supernatant) resulting from the Amicon Ultra Centrifugal Filter separation ranged
between 0-6 ng/mL, and those obtained using the regular brain homogenization method ranged
between 0-1 ng/mL (Fig. 2). Seven of the brains separated using the Amicon Ultra Centrifugal Filters,
but only two of the brains separated using the regular brain homogenization method, were above the
saline concentration threshold (Fig. 2). Notably, ﬁve of the brains treated with the cTfRMAb-N292GEPO had brain concentrations within the saline concentration threshold while using either the Amicon
or the regular brain homogenization separation method. This is an expected ﬁnding given the known
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Fig. 2. The concentration of cTfRMAb-based fusion proteins in mouse brain homogenates. In the above-paired graph, each
symbol-line-symbol represents the paired brain concentrations resulting post-ELISA by the brain homogenization and Amicon
concentration method for the same brain. Each symbol-line-symbol represents an individual brain from a mouse treated either
with cTfRMAb-EPO, cTfRMAb-N292G-EPO, or saline. The red dotted line represents the limit of detection of the assay (0.8
ng/mL).

profound differences in plasma clearance and thereby the resultant brain concentrations between the
two cTfRMAb-based fusion proteins. The cTfRMAb-EPO has a higher plasma exposure and half-life
with a lower clearance compared to that of the cTfRMAb-N292G-EPO [8]. As a result, the expected
brain concentrations of the cTfRMAb-N292G-EPO are low at the doses used in the current study.
We then converted the ng/mL brain homogenate supernatant concentrations to brain
concentrations in ng/g brain tissue. After intravenous administration, the Amicon Ultra Centrifugal
Filter separated group displayed a signiﬁcantly higher (p < 0.0 0 01) brain concentration (ng/g brain)
compared to the brain homogenate group for cTfRMAb-EPO, and a similar trend was seen for
the cTfRMAb-N292G-EPO fusion protein, though these values did not reach statistical signiﬁcance
(Fig. 3A). As seen in Fig. 3A, as expected based on the plasma pharmacokinetics [8], the brain
concentrations of the cTfRMAb-EPO were signiﬁcantly (p < 0.001) higher than those of cTfRMAbN292G-EPO and saline for the Amicon Ultra Centrifugal Filter separated group. The cTfRMAb-EPO
group was 8-fold larger in brain concentration (ng/g brain) compared to the cTfRMAb-N292G-EPO
group and was 642-fold larger in brain concentration compared to the saline group (Fig. 3A). The
regular brain homogenization method was unable to detect any signiﬁcant differences between
the three groups (Fig. 3A). These trends are also conﬁrmed following the intraperitoneal route of
administration.
After intraperitoneal administration, the Amicon Ultra Centrifugal Filter separated group displayed
a trend (p = 0.054) towards a higher signal compared to the brain homogenate group for cTfRMAbEPO. This trend was not observed for cTfRMAb-N292G-EPO because of the below-detection brain
concentrations of cTfRMAb-N292G-EPO following intraperitoneal administration at the doses used in
the current study (Fig. 2). Again, as expected, the brain concentrations of the cTfRMAb-EPO were
signiﬁcantly (p < 0.01) higher than those of the cTfRMAb-N292G-EPO and saline for the Amicon Ultra
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Fig. 3. The brain concentrations of the cTfRMAb-based fusion proteins following intravenous (A) and intraperitoneal (B)
administration of a 3 mg/kg dose of each fusion protein comparing the Amicon Ultra Centrifugal Filter separated group and
the regular brain homogenate group. The Amicon Ultra Centrifugal Filter data was presented in reference [8]. The data was
analyzed using the two-way ANOVA with Holm-Sidak multiple comparisons test. All data are represented as mean ± standard
error of the mean (SEM). ∗ ∗ P < 0.01 and ∗ ∗ ∗ ∗ P < 0.0 0 01. $ P < 0.0 0 01 in A and p = 0.054 in B represent comparisons to the
corresponding Amicon Ultra Centrifugal Filter separated group.

Centrifugal Filter separated group (Fig. 3B). Similar to the intravenous administration, the regular brain
homogenization method was unable to detect any signiﬁcant differences between the three groups
(Fig. 3B).
Overall, while comparing the Amicon Ultra Centrifugal Filter separated method with the regular
brain homogenization method, the Amicon separation method concentrated the brain homogenate
supernatant for the cTfRMAb-based fusion proteins tested in the current study. This concentration
of the brain homogenate supernatant signiﬁcantly increased the signal for the ELISA which allowed
the detection of expected differences in the brain concentrations of the two different cTfRMAbbased fusion proteins tested herein using the Amicon separation method; these differences were not
detected by the regular brain homogenization method. We attribute this improvement of the signal
with the Amicon Ultra Centrifugal Filters to 1) the concentration of the brain homogenate volume
which results in the enrichment of the brain homogenate for the analyte of interest, and 2) cleanup of the brain homogenate supernatant owing to the 50kDa molecular weight cut-off ﬁlters and
therefore an expected reduction in the samples matrix-effect. The use of centrifugal ﬁltration devices
for sample clean-up has been previously reported for small molecule quantiﬁcation in biological
samples prior to liquid chromatography coupled with mass spectrometry (LC-MS) [10]. Besides the use
of the Amicon Ultra Centrifugal Filters, there are other sample clean-up techniques including solidphase extraction (SPE) that are extensively used for sample preparation to measure large molecules
such as antibody-drug conjugates (ADCs) prior to LC-MS quantiﬁcation [11]. However, the use of SPE is
more time consuming than simple centrifugation-based separation, and its use for sample preparation
to measure the brain concentrations of IgG-biologic fusion proteins has not been reported and
requires further investigation. Further, though LC-MS quantiﬁcation is widely used to measure ADCs
in biological samples and can have a reported limit of detection of 1 ng/mL [12], the measurement
of IgG-biologic fusion proteins is further complicated due to their even larger size and diﬃculty in
interpretation of the mass signal [11]. Furthermore, measurement of in vivo brain concentrations of
IgG-biologic fusion proteins with this method has not been reported yet but may be a viable approach
[13] that needs to be further investigated.
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The most widely used technique to sensitively measure brain concentrations of IgG-biologic
fusion proteins is radiolabeling of the fusion protein. The use of sandwich immunoassays such
as ELISA and the electrochemiluminescence-Meso Scale Discovery (ECL-MSD) platforms to measure
brain concentrations of IgG-biologic fusion proteins has increased considerably in the last decade
and offers the advantage of being non-radioactive approaches. However, sample preparation for
these immunoassays can result in sample loss compared to using radioactive methods. Other nonradioactive approaches used to measure brain concentrations of IgG-biologic fusion proteins include
near infrared ﬂuorescence (NIRF) imaging and immunostaining techniques [14,15], however these
techniques are semi-quantitative. The current study shows promise in the use of Amicon Centrifugal
Filters to enhance the signal of a quantitative sandwich ELISA to measure the brain concentrations of
IgG-EPO fusion proteins, and future work is needed to see if this technique can be widely applied to
other IgG-biologic fusion proteins.
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